Jordi Carrera is the CEO of STAT-Diagnostica, the company developing DiagCORE, an in-vitro diagnostic system that will allow medical staff to carry out up to fifteen molecular diagnosis and immunoassay tests.
Dr. Pere Joan Cardona, co-founder of Manremyc along with Dr. Cristina Vilaplana, Isabel Amat and Jaume Amat. He is head of research for a revolutionary product to fight tuberculosis. This spin-off of the Germans Trias i Pujol Health Sciences Research Institute will launch a nutraceutic targeting this bacillus on the Indian market in the second half of 2015, which may in the long term eradicate this disease. Pere Joan Cardona participated in the BioEmprenedorXXI awards.
Carlos Buesa is the CEO of Oryzon Genomics, a clinical biotechnology company he founded in 2000 along with Tamara Maes. Oryzon Genomics, leader in Europe in epigenetics, has signed the largest agreement between a Catalan biotech firm and a multinational pharmaceutical corporation, Swiss-based Roche.
Pau Soler is the co-founder at MIRU Medical Systems. He has a degree in Telecommunications Engineering and a PhD in Medical Imaging. He later complemented his professional degree with training in marketing and entrepreneurship in the United States. Influenced by his father, a doctor and inventor, Soler has found a way to combine his two callings: generating value through a company that applies medical technology to benefit society.
Jorge is the Head of Academics at Moebio, where he leads the d·HEALTH Barcelona program. He is the Director of e-Health and Health 2.0 at Hospital Sant Joan de Déu. He has over 15 years of experience in life sciences and healthcare, with a strong focus on tech, innovation and entrepreneurship. He acts as mentor to various healthcare start-ups and entrepreneurial acceleration programs. He is a graduate from the London School of Economics and he also holds a GMP from IESE Business School and a GSP from Singularity University. He's been selected as 2014 European Young Leader 40 Under 40.
PhD in Computational Biology and ICREA researcher.
Aloy and his team have taken part in European projects like SyStemAge to study ageing in human stem cells, and they have also carried out their own researches like the one on how to detect and prevent drug side effects.
Head of the Translational Genomics Group at the Vall d'Hebron Institute of Oncology (VHIO) and oncologist at the Vall d'Hebron University Hospital.
For his research on breast cancer diagnosis and treatment, he has been awarded with the Career Catalyst Research Grant by the American foundation Susan G. Komen for the Cure, a prize given for the first time in Spain and endowed with €345,000. .
PhD in clinical neurology from the University of Alicante and MBA from ESADE Business School. He has also participated in executive programs at IESE and Harvard. For more than 20 years, he has held top executive positions at national and international pharmaceutical companies like Parke-Davis (now Pfizer), UCB Pharma, Grup Uriach and Isdin (Esteve Group). In 2009, he founded the biotechnology firm SOM Biotech and is currently fully devoted to growing the company.
Degree in Technical Engineering in Telecommunications from La Salle. He joined the biotechnology at Archivel Technologies. He was general manager of Archivel Farma, during which time the company carried out phase I trials on the Ruti vaccine for latent tuberculosis, and participated in the creation of Laboratorios Argos. He created Bioemprèn from which he continues to promote ideas and business projects in the biotechnology arena in Catalonia. He has been CEO of Specific Pig and Rob Surgical Systems and a member of the Board of Directors at VCN Biosciences and Manremyc.
President of the Barcelona Respiratory Network (BRN)
He holds a PhD in Medicine from UB specializing in pulmonology. He has headed up the Barcelona Hospital Clínic Thorax Institute and since 2006 has been scientific director of the Networked Centre for Biomedical Research on Respiratory Diseases. He's one of the leading researchers in translational research to improve diagnosis and treatment of chronic obstructive pulmonary disease and has been a member of the Executive Committee of the European Respiratory Society. His newest challenge is presiding over the BRN to bring a global spotlight to Catalan research in respiratory disease.